Hernández-del Rio JE, Becerra-Martínez JC, Galindo-Gil S, Chávez-Alvado JC, Petersen-Aranguren F

Idioma: Español
Referencias bibliográficas: 13
Paginas: 192-166
Archivo PDF: 581.28 Kb.

RESUMEN

El síndrome antifosfolípidos (SAF) es poco frecuente, está caracterizado por complicaciones asociadas a un estado de hipercoagulabilidad. El SAF incluye características clínicas como: trombosis arterial o venosa, enfermedad de arterias coronarias, formación de trombo intracardiaco, hipertensión pulmonar, miocardiopatía dilatada y enfermedad valvular, siendo la más afectada la válvula mitral seguida de la aórtica y tricúspide.
El diagnóstico de SAF se lleva a cabo mediante la detección de anticuerpos antifosfolípidos (AAF). Presentamos el caso de un paciente con cardiopatía isquémica secundaria a un Síndrome antifosfolípidos primario.

REFERENCIAS (EN ESTE ARTÍCULO)

1. 1. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification riteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295–306

2. Hughes GR. Hughes syndrome (the antiphospholipid syndrome): ten clinical lessons. Autoimmun Rev. 2008; 7:262–266

3. Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1000 patients. Arthritis Rheum 2002; 46:1019–1027

4. Cervera R, Khamashta MA, Shoenfeld Y, et al.Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis 2009; 68:1428–1432

5. Alonso-Santor JE, Inglada-Galiana L, Pérez-Paredes G. The antiphospholipid syndrome: an update. An Med Interna 2007; 24(5):242-248

6. Font J, Cervera R. Cardiac manifestations in antiphospholipid syndrome. In: Khamashta MA (ed) Hughes syndrome, 2nd edn, 2006. Springer, London, pp 41–53

7. Bick RL, Baker WF. Treatment Options for Patients Who Have Antiphospholipid Syndromes. Hematol Oncol Clin North Am. 2008;22(1):145-153.

8. Soltesz P, Veres K, Lakos G, et al. Evaluation of clinical and laboratory features of antiphospholipid syndrome: a retrospective study of 637 patients. Lupus 2003; 12(4):302–7.

9. Vaarala O, Alfthan G, Jauhiainen M, et al. Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet 1993;341(8850):923–5.

10. 10.Hamsten A, Norberg R, Bjorkholm M, et al. Antibodies to cardiolipin in young survivors of myocardial infarction: an association with recurrent cardiovascular events. Lancet 1986;1(8473):113–6.

11. 11.Morton KE, Gavaghan TP, Krilis SA, et al. Coronar y ar ter y bypass graft failure—an autoimmune phenomenon? Lancet 1986;2(8520):1353–7.

12. 12.Koniari I, Siminelakis SN, Baikoussis NG, Papadopoulos G, Goudevenos J, Apostolakis E. Antiphospholipid syndrome; its implication in cardiovascular diseases: a review. J Cardiothorac Surg. 2010 Nov 3;5:101.

13. Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GR. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med. 1995 Apr 13;332(15):993-7